23. Rana S., Karumanchi S.A., Lindheimer M.D. Angiogenic factors in diagnosis, management, and research in pre-eclampsia. Hypertension. 2014; 63 (2): 198-202. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.113.02293
24. Myatt L., Clifton R.G., Roberts J.M., Spong C.Y., Wapner R.J., Thorp J.M. Jr, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of preeclampsia in a low-risk nulliparous patient population? BJOG. 2013; 120 (10): 1183-91. DOI: https://doi.org/10.1111/1471-0528.12128
25. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. Competing risks model in early screening for pre-eclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013; 33 (1): 8-15. DOI: https://doi.org/10.1159/000341264
26. Park H.J., Kim S.H., Jung Y.W., Shim S.S., Kim J.Y., Cho Y.K., et al. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childb. 2014; 14: 35. DOI: https://doi.org/10.1186/1471-2393-14-35
27. Mutter W.P., Karumanchi S.A. Molecular mechanisms of pre-eclampsia. Microvasc Res. 2008; 75 (1): 1-8. DOI: https://doi.org/10.1016/j.mvr.2007.04.009
28. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355 (10): 992-1005. DOI: https://doi.org/10.1056/NEJMoa055352
29. Sachan R., Patel M.L., Dhiman S., Gupta P., Sachan P., Shyam R. Diagnostic and prognostic significance of serum soluble endoglin levels in preeclampsia and eclampsia. Adv Biomed Res. 2016; 5: 119. DOI: https://doi.org/10.4103/2277-9175.186993
30. Robinson J., Johnson D.D. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007; 197 (2): 174.e1-5. DOI: https://doi.org/10.1016/j.ajog.2007.03.058
31. Maynard S., Simas T.A.M., Bur L., Crawford S.L., Solitro M.J., Meyer B.A. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregnancy. 2010; 29 (3): 330-41. DOI: https://doi.org/10.3109/10641950902968684
32. Lawrence J.B., Oxvig C., Overgaard M.T., Sottrup-Jensen L., Gleich G.J., Hays L.G., et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA. 1999; 96 (6): 3149-53. DOI: https://doi.org/10.1073/pnas.96.6.3149
33. Deveci K., Sogut E., Evliyaoglu O., Duras N. Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. J Obstet Gynaecol Res. 2009; 35 (1): 94-8. DOI: https://doi.org/10.1111/j.1447-0756.2008.00835.x
34. Bersinger N.A., Odegard R.A. Second- and third-trimester serum levels of placental proteins in pre-eclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004; 83 (1): 37-45. PMID: 14678084;
35. Bersinger N.A., Smarason A.K., Muttukrishna S., Groome N.P., Redman C.W. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy. 2003; 22 (1): 45-55. DOI: https://doi.org/10.1081/PRG-120016794
36. Smith G.C., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, pre-eclampsia, and stillbirth. J Clin Endocrinol Metab. 2002; 87 (4): 1762-7. DOI: https://doi.org/10.1177/1933719113512532
37. Luewan S., Teja M., Sirichotiyakul S., Tongsong T. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018; 59 (1): 55-9. DOI: https://doi.org/10.11622/smedj.2017034
38. Adamyan L.V., Artymuk N.V., Bashmakova N.V. et al. Hypertensive disorders during pregnancy, in the labor and postpartum period. Preeclampsia. Eclampsia. Clinical recommendations (protocol). Ministry of Health service of Russian Federation on June 7, 2016 No. 15-4/10/2-3484. Moscow, 2016. (in Russian) [Адамян Л.В., Артымук Н.В., Башмакова Н.В., Белокринницкая Т.Е., Беломестнов С.Р., Братищев И.В. и др. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол), утв. МЗ РФ 7 июня 2016 № 15-4/10/2-3484. Москва, 2016.]
39. Sibai B.M., Koch M.A., Freire S., Pinto e Silva J.L., Rudge M.V., Martins-Costa S., et al. Serum inhibin-A and angiogenic factor levels in pregnancies with previous pre-eclampsia and/or chronic hypertension: Are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol. 2008; 199 (3): 268.e1-9. DOI: https://doi.org.10.1016/j.ajog.2008.06.071
40. Muttukrishna S., North R.A., Morris J., Schellenberg J.C., Taylor R.S., Asselin J., et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod. 2000; 15 (7): 1640-5. DOI: https://doi.org/10.1093/humrep/15.7.1640
41. Kang J.H., Farina A., Park J.H., Kim S.H., Kim J.Y., Rizzo N., et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: Correlation with the week of onset and the severity. Prenat Diagn. 2008; 28 (8): 704-9. DOI: https://doi.org/10.1002/pd.1997
42. Ree P.H., Hahn W.B., Chang S.W., Jung S.H., Kang J.H., Cha D.H., et al. Early detection of preeclampsia using inhibin-A and other second-trimester serum markers. Fetal Diagn Ther. 2011; 29 (4): 280-6. DOI: https://doi.org/10.1159/000322742
43. Ong C.Y., Liao A.W., Munim S., Spencer K., Nicolaides K.H. First-trimester maternal serum activin-A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med. 2004; 15 (3): 176-80. DOI: https://doi.org/10.1080/14767050410001668275
44. Salomon L.J., Benattar C., Audibert F., Fernandez H., Duyme M., Taieb J., et al. Severe pre-eclampsia is associated with high inhibin-A levels and normal leptin levels at 7 to 13 weeks into pregnancy. Am J Obstet Gynecol. 2003; 189 (3): 1517-22. DOI: https://doi.org/10.1016/s0002-9378(03)00902-5
45. Than N.G., Romero R., Goodman M., Weckle A., Xing J., Dong Z., et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA. 2009; 106 (24): 9731-6. DOI: https://doi.org/10.1073/pnas.0903568106
46. Than N.G., Romero R., Kim C.J., McGowen M.R., Papp Z., Wildman D.E. Galectins: Guardians of eutherian pregnancy at the maternal-fetal interface. Trends Endocrinol Metab. 2012; 23 (1): 23-31. DOI: https://doi.org/10.1016/j.tem.2011.09.003
47. Huppertz B. Placental origins of pre-eclampsia: Challenging the current hypothesis. Hypertension. 2008; 51 (4): 970-5. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.107.107607
48. Huppertz B., Sammar M., Chefetz I., Neumaier-Wagner P., Bartz C., Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther. 2008; 24 (3): 230-6. DOI: https://doi.org/10.1159/000151344
49. Soongsatitanon A., Phupong V. Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med. 2022; 35 (22): 4412-7. DOI: https://doi.org/10.1080/14767058.2020.1849127
50. Gonen R., Shahar R., Grimpel Y.I., Chefetz I., Sammar M., Meiri H., et al. Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 2008; 115 (12): 1465-72. DOI: https://doi.org/10.1111/j.1471-0528.2008.01902.x
51. Akolekar R., Syngelaki A., Beta J., Kocylowski R., Nicolaides K.H. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn. 2009; 29 (12): 1103-8. DOI: https://doi.org/10.1002/pd.2375
52. Cuckle H.S. Screening for pre-eclampsia - lessons from aneuploidy screening. Placenta. 2011; 32: S42-8. DOI: https://doi.org/10.1016/j.placenta.2010.07.015
53. Nicolaides K.H., Bindra R., Turan O.M., Chefetz I., Sammar M., Meiri H., et al. A novel approach to first-trimester screening for early preeclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006; 27 (1): 13-7. DOI: https://doi.org/10.1002/uog.2686
54. Chafetz I., Kuhnreich I., Sammar M., Tal Y., Gibor Y., Meiri H., et al. First-trimester placental protein 13 screening for pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007; 197 (1): 35.e1-7. DOI: https://doi.org/10.1016/j.ajog.2007.02.025
55. Meiri H., Sammar M., Herzog A., Grimpel Y.I., Fihaman G., Cohen A., et al. Prediction of pre-eclampsia by placental protein 13 and background risk factors and its prevention by aspirin. J Perinat Med. 2014; 42 (5): 591-601. DOI: https://doi.org/10.1515/jpm-2013-0298
56. Loechel F., Fox J.W., Murphy G., Albrechtsen R., Wewer U.M. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun. 2000; 278 (3): 511-5. DOI: https://doi.org/10.1074/jbc.M409565200
57. Spencer K., Cowans N.J., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008; 28 (3): 212-6. DOI: https://doi.org/10.1002/pd.1957
58. Poon L.C., Chelemen T., Granvillano O., Pandeva I., Nicolaides K.H. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol. 2008; 112 (5): 1082-90. DOI: https://doi.org/10.1097/AOG.0b013e318188d6f9
59. Laigaard J., Sorensen T., Placing S., Holck P., Frohlich C., Wojdemann K.R., et al. Reduction of the disintegrin and metalloprotease ADAM12 in pre-eclampsia. Obstet Gynecol. 2005; 106 (1): 144-9. DOI: https://doi.org/10.1097/01.aog.0000165829.65319.65
60. Goetzinger K.R., Zhong Y., Cahill A.G., Odibo L., Macones G.A., Odibo A.O. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013; 32 (9): 1593-600. DOI: https://doi.org/10.7863/ultra.32.9.1593
61. Kristensen K., Larsson I., Hansson S.R. Increased cystatin C expression in the preeclamptic placenta. Mol Hum Reprod. 2007; 13 (3): 189-95. DOI: https://doi.org/10.1093/molehr/gal111
62. Thilaganathan B., Ralph E., Papageorghiou A.T., Melchiorre K., Sheldon J. Raised maternal serum cystatin C: An early pregnancy marker for pre-eclampsia. Reprod Sci. 2009; 16 (8): 788-93. DOI: https://doi.org/10.1177/1933719109336618
63. Souza D.G., Soares A.C., Pinho V., Torloni H., Reis L.F., Teixeira M.M., et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol. 2002; 160 (5): 1755-65. DOI: https://doi.org/10.1016/s0002-9440(10)61122-4
64. Cetin I., Cozzi V., Pasqualini F., Nebuloni M., Garlanda C., Vago L., et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006; 194 (5): 1347-53. DOI: https://doi.org/10.1016/j.ajog.2005.11.018
65. Polgar J., Matuskova J., Wagner D.D. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005; 3 (8): 1590-6. DOI: https://doi.org/10.1111/j.1538-7836.2005.01373.x
66. Dunlop L.C., Skinner M.P., Bendall L.J., Favaloro E.J., Castaldi P.A., Gorman J.J., et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med. 1992; 175 (4): 1147-50. DOI: https://doi.org/10.1084/jem.175.4.1147
67. Holthe M.R., Staff A.C., Berge L.N., Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol. 2004; 190 (4): 1128-34. DOI: https://doi.org/10.1016/j.ajog.2003.10.699
68. Konijnenberg A., Stokkers E.W., van der Post J.A., Schaap M.C., Boer K., Bleker O.P., et al. Extensive platelet activation in pre-eclampsia compared with normal pregnancy: Enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 1997; 176 (2): 461-9. DOI: https://doi.org/10.1016/s0002-9378(97)70516-7
69. Yoneyama Y., Suzuki S., Sawa R., Kiyokawa Y., Power G.G., Araki T. Plasma adenosine levels and P-selectin expression on platelets in pre-eclampsia. Obstet Gynecol. 2001; 97 (3): 366-70. DOI: https://doi.org/10.1016/s0029-7844(00)01184-4
70. Bretelle F., Sabatier F., Desprez D., Camoin L., Grunebaum L., Combes V., et al. Circulating microparticles: A marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost. 2003; 89 (3): 486-92. PMID: 12624632.
71. Lok C.A., Nieuwland R., Sturk A., Hau C.M., Boer K., Vanbavel E., et al. Microparticle-associated P-selectin reflects platelet activation in pre-eclampsia. Platelets. 2007; 18 (1): 68-72. DOI: https://doi.org/10.1080/09537100600864285
72. Aksoy H., Kumtepe Y., Akcay F., Yildirim A.K. Correlation of P-selectin and lipoprotein(a), and other lipid parameters in pre-eclampsia. Clin Exp Med. 2002; 2 (1): 39-43. DOI: https://doi.org/10.1007/s102380200005
73. Heyl W., Handt S., Reister F., Gehlen J., Schroder W., Mittermayer C., et al. Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation. Eur J Obstet Gynecol Reprod Biol. 1999; 86 (1): 35-41. DOI: https://doi.org/10.1016/s0301-2115(99)00042-1
74. Halim A., Kanayama N., el Maradny E., Nakashima A., Bhuiyan A.B., Khatun S., et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in pre-eclampsia and eclampsia: their significances. Am J Obstet Gynecol. 1996; 174 (1 pt 1): 272-7. DOI: https://doi.org/10.1016/s0002-9378(96)70407-6
75. Chaiworapongsa T., Romero R., Yoshimatsu J., Espinoza J., Kim Y.M., Park K., et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med. 2002; 12 (1): 19-27. DOI: https://doi.org/10.1080/jmf.12.1.19.27
76. Nasrollahi S., Hoseini Panah S.M., Tavilani H., Tavasoli S., Naderan M., Shoar S. Antioxidant status and serum levels of selectins in pre-eclampsia. J Obstet Gynaecol. 2015; 35 (1): 16-8. DOI: https://doi.org/10.3109/01443615.2014.935710
77. Zhang Y., Yang H., Long Y., Ma Q., Chen R. Plasma level of placenta-derived macrophage-stimulating protein-chain in preeclampsia before 20 weeks of pregnancy. PLoS One. 2016; 11 (8): e0161626. DOI: https://doi.org/10.1371/journal.pone.0161626
78. Olsson M.G., Centlow M., Rutardottir S., Stenfors I., Larsson J., Hosseini-Maaf B., et al. Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger alpha(1)-microglobulin in preeclampsia. Free Radic Biol Med. 2010; 48 (2): 284-91. DOI: https://doi.org/10.1016/j.freeradbiomed.2009.10.052
79. Hansson S.R., Gram M., Akerstrom B. Fetal hemoglobin in pre-eclampsia: A new causative factor, a tool for prediction/diagnosis and a potential target for therapy. Curr Opin Obstet Gynecol. 2013; 25 (6): 448-55. DOI: https://doi.org/10.1097/GCO.0000000000000022
80. Centlow M., Carninci P., Nemeth K., Mezey E., Brownstein M., Hansson S.R. Placental expression profiling in pre-eclampsia: Local overproduction of hemoglobin may drive pathological changes. Fertil Steril. 2008; 90 (5): 1834-43. DOI: https://doi.org/10.1016/j.fertnstert.2007.09.030
81. Gram M., Anderson U.D., Johansson M.E., Edström-Hägerwall A., Larsson I., Jälmby M., et al. Correction: The human endogenous protection system against cell-free hemoglobin and heme is overwhelmed in preeclampsia and provides potential biomarkers and clinical indicators. PLoS One. 2020; 15 (2): e0229816. DOI: https://doi.org/10.1371/journal.pone.0229816
82. Anderson U.D., Gram M., Ranstam J., Thilaganathan B.; Kerstrom B., Hansson S.R. Fetal hemoglobin, a1-microglobulin and hemopexin are potential predictive first trimester biomarkers for preeclampsia. Pregnancy Hypertens. 2016; 6 (2): 103-9. DOI: https://doi.org/10.1016/j.preghy.2016.02.003
83. Anderson U.D., Olsson M.G., Rutardóttir S., Centlow M., Kristensen K.H., Isberg P.E., et al. Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. Am J Obstet Gynecol. 2011; 204 (6): 520.e1-5. DOI: https://doi.org/10.1016/j.ajog.2011.01.058
84. Fong F.M., Sahemey M.K., Hamedi G., Eyitayo R., Yates D., Kuan V., et al. Maternal genotype and severe pre-eclampsia: A HuGE review. Am J Epidemiol. 2014; 180 (4): 335-45. DOI: https://doi.org/10.1093/aje/kwu151
85. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Ante- and postnatal risk factors of venous thrombosis: A hospital-based case-control study. J Thromb Haemost. 2008; 6 (6): 905-12. DOI: https://doi.org/10.1111/j.1538-7836.2008.02961.x
86. Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium (Greentop Guideline No 37a). London: RCOG, 2015. URL: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg37a.pdf
87. Sultan A.A., Grainge M.J., West J., Fleming K.M., Nelson-Piercy C., Tata L.J. Impact of risk factors on the timing of first postpartum venous thromboembolism: A population-based cohort study from England. Blood. 2014; 124 (18): 2872-80. DOI: https://doi.org/10.1182/blood-2014-05-572834
88. Benschop L., Duvekot J.J., van Lennep R.J.E. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019; 105 (16): 1273-8. DOI: https://doi.org/10.1136/heartjnl-2018-313453
89. Thilaganathan B., Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019; 73 (3): 522-31. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.11191
90. Buurma A.J., Turner R.J., Driessen J.H., Mooyaart A.L., Schoones J.W., Bruijn J.A., et al. Genetic variants in pre-eclampsia: A meta-analysis. Hum Reprod Update. 2013; 19 (3): 289-303. DOI: https://doi.org/10.1093/humupd/dms060
91. Alsnes I.V., Vatten L.J., Fraser A., Bjørngaars J.H., Rich-Edwards J., Romundstad P.R., et al. Hypertension in pregnancy and offspring cardiovascular risk in young adulthood: Prospective and sibling studies in the HUNT study (Nord-Trondelag Health Study) in Norway. Hypertension. 2017; 69 (4): 591-8. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.116.08414
92. Leon L.J., McCarthy F.P., Direk K., Gonzalez-Izquierdoo A., Prieto-Merino D., Casas J.P., et al. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: A CALIBER study. Circulation. 2019; 140 (13): 1050-60. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.038080
93. Paré E., Parry S., McElrath T.F., Pucci D., Newton A., Lim K.-H. Clinical risk factors for preeclampsia in the 21st century. Obstet Gynecol. 2014; 124 (4): 763-70. DOI: https://doi.org/10.1097/AOG.0000000000000451
94. Peixoto A.B., Araujo Júnior E., Ribeiro J.U., Rocha Rodrigues D.B., Cunha Castro E.C., Cunha Caldas T.M.R., et al. Evaluation of inflammatory mediators in the deciduas of pregnant women with pre-eclampsia/eclampsia. J Matern Fetal Neonatal Med. 2016; 29 (1): 75-9. DOI: https://doi.org/10.3109/14767058.2014.987117
95. Regal J.F., Burwick R.M., Fleming S.D. The complement system and preeclampsia. Curr Hypertens Rep. 2017; 19 (11): 87. DOI: https://doi.org/10.1007/s11906-017-0784-4
96. Sudo M., Yoshita K., Ito Y., Imai N., Iino N., Narita I. Histopathological features of kidney and renal prognosis in patients with preeclampsia. Pregnancy Hypertens. 2021; 25: 75-80. DOI: https://doi.org/10.1016/j.preghy.2021.05.015
97. Isaacs A., Cox R.A., Rotem Z. Foreign nucleic acids as the stimulus to make interferon. Lancet. 1963; 2 (7299): 113-6. DOI: https://doi.org/10.1016/s0140-6736(63)92585-6
98. Scharfe-Nugent A., Corr S.C., Carpenter S.B., Keogh L., Doyle B., Martin C., et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol. 2012; 188 (11): 5706-12. DOI: https://doi.org/10.4049/jimmunol.1103454
99. Cotter A.M., Martin C.M., O’Leary J.J., Daly S.F. Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of pre-eclampsia. Am J Obstet Gynecol. 2004; 191 (2): 515-20. DOI: https://doi.org/10.1016/j.ajog.2004.01.040
100. Miranda M.L., Macher H.C., Munoz-Hernandez R., Vallejo-Vaz A., Moreno-Luna R., Villar J., et al. Role of circulating cell-free DNA levels in patients with severe pre-eclampsia and HELLP syndrome. Am J Hypertens. 2013; 26 (12): 1377-80. DOI: https://doi.org/10.1093/ajh/hpt187
101. Tjoa M.L., Cindrova-Davies T., Spasic-Boskovic O., Bianchi D.W., Burton G.J. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol. 2006; 169 (2): 400-4. DOI: https://doi.org/10.2353/ajpath.2006.060161
102. Lo Y.M., Leung T.N., Tein M.S., Sargent I.L., Zhang J., Lau T.K., et al. Quantitative abnormalities of fetal DNA in maternal serum in pre-eclampsia. Clin Chem. 1999; 45 (2): 184-8. PMID: 9931039.
103. Grill S., Rusterholz C., Zanetti-Dallenbach R., Tercanli S., Holzgreve W., Hahn S., et al. Potential markers of pre-eclampsia - a review. Reprod Biol Endocrinol. 2009; 7: 70. DOI: https://doi.org/10.1186/1477-7827-7-70
104. Martin A., Krishna I., Martina B., Samuel A. Can the quantity of cell-free fetal DNA predict pre-eclampsia: A systematic review. Prenat Diagn. 2014; 34 (7): 685691. DOI: https://doi.org10.1002/pd.4416
105. Papantoniou N., Bagiokos V., Agiannitopoulos K., Kolialexi A., Destouni A., Tounta G., et al. RASSF1A in maternal plasma as a molecular marker of pre-eclampsia. Prenat Diagn. 2013; 33 (7): 682-7. DOI: https://doi.org/10.1002/pd.4093
106. Enquobahrie D.A., Abetew D.F., Sorensen T.K., Willoughby D., Chidambaram K., Williams M.A. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2011; 204 (2): 178.e12-21. DOI: https://doi.org/10.1016/j.ajog.2010.09.004
107. Mayor-Lynn K., Toloubeydokhti T., Cruz A.C., Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci. 2011; 18 (1): 4656. DOI: https://doi.org/10.1177/1933719110374115
108. Choi S.Y., Yun J., Lee O.J., Han H.S., Yeo M.K., Lee M.A., et al. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013; 34 (9): 799-804. DOI: https://doi.org/101016/j.placenta.2013.06.006
109. Pineles B.L., Romero R., Montenegro D., Tarca A.L., Han Y.M., Kim Y.M., et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007; 196 (3): 261.e1-6. DOI: https://doi.org/10.1016/j.ajog.2007.01.008
110. Zhu X.M., Han T., Sargent I.L., Yin G.W., Yao Y.Q. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs. normal pregnancies. Am J Obstet Gynecol. 2009; 200 (6): 661.e1-7. DOI: https://doi.org/10.1016/j.ajog.2008.12.045
111. Nizyaeva N.V., Kan N.E., Tyutyunnik V.L., et al. MicroRNAs As an important precursors of diagnostic obstetric pathology. Vestnik Rossiiskoy akademii meditsinskikh nauk [Annals of the Russian Academy of Medical Sciences]. 2015; 70 (4): 484-92. DOI: https://doi.org/10.15690/vramn.v70.i4.1416 (in Russian) [Низяева Н.В., Кан Н.Е., Тютюнник В.Л. и др. МикроРНК как важные диагностичеcкие предвестники развития акушерской патологии // Вестник Российской академии медицинских наук. 2015. Т. 70, № 4. C. 484-492. DOI: https://doi.org/10.15690/vramn.v70.i4.1416]
112. Yin Y., Liu M., Yu H., Zhang J., Zhou R. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 253: 121-32. DOI: https://doi.org/10.1016/j.ejogrb.2020.08.016
113. Murphy M.S., Casselman R.C., Tayade C., Smith G.N. Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum. Am J Obstet Gynecol. 2015; 213 (3): 367.e1-9. DOI: https://doi.org/10.1016/j.ajog.2015.05.013
114. Hromadnikova I. Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency. DNA Cell Biol. 2012; 31 (7): 1221-32. DOI: https://doi.org/10.1089/dna.2011.1530
115. Hromadnikova I., Kotlabova K., Doucha J., Dlouha K., Krofta L. Absolute and relative quantification of placenta-specific microRNAs in maternal circulation with placental insufficiency-related complications. J Mol Diagn. 2012; 14 (2): 160-7. DOI: https://doi.org/10.1016/j.jmoldx.2011.11.003
116. Pan M., Ge Q., Li H., Yang Q., Lu J., Zhang D., et al. Sequencing the miRNAs in maternal plasma from women before and after parturition. J Nanosci Nanotechnol. 2012; 12 (5): 4035-43. DOI: https://doi.org/10.1166/jnn.2012.6196
117. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54 (3): 482-90. DOI: https://doi.org/10.1373/clinchem.2007.097972
118. Sheikh A.M., Small H.Y., Currie G., Delles C. Systematic review of micro-RNA expression in pre-eclampsia identifies a number of common pathways associated with the disease. PLoS One. 2016; 11 (8): e0160808. DOI: https://doi.org/10.1371/journal.pone.0160808
119. Tarca A.L., Romero R., Erez O., Gudicha D.W., Than N.G., BenshalomTirosh N., et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: A longitudinal study. J Matern Fetal Neonatal Med. 2020; 34 (21): 3463-74. DOI: https://doi.org/10.1080/14767058.2019.1685964
120. Hromadnikova I., Dvorakova L., Kotlabova K., Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci. 2019; 20 (12): 2972. DOI: https://doi.org/10.3390/ijms20122972
121. Bellos I., Pergialiotis V., Papapanagiotou A. Association between serum copeptin levels and preeclampsia risk: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 250: 66-73. DOI: https://doi.org/10.1016/j.ejogrb.2020.04.051
122. Huhn E.A., Hoffmann I., De Tejada B.M., Lange S., Sage K.M., Roberts C.T., et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childb. 2020; 20 (1): 128. DOI: https://doi.org/10.1186/s12884-020-2809-2
123. Wu Y., Xiong X., Fraser W.D., Luo Z.C. Association of uric acid with progression to preeclampsia and development of adverse conditions in gestational hypertensive pregnancies. Am J Hypertens. 2012; 25 (6): 711-7. DOI: https://doi.org/10.1038/ajh.2012.18
124. Roberts J.M., Bodnar L.M., Lain K.Y., Hubel C.A, Markovic N., Ness R.B., et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension. 2005; 46 (6): 1263-9. DOI: https://doi.org/10.1161/01.HYP.0000188703.27002.14
125. Hawkins T.L., Roberts J.M., Mangos G.J., Davis G.K., Roberts L.M., Brown M.A. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: A retrospective cohort study. BJOG. 2012; 119 (4): 484-92. DOI: https://doi.org/10.1111/j.1471-0528.2011.03232.x
126. Bellomo G., Venanzi S., Saronio P., Verdura C., Narducci P.L. Prognostic significance of serum uric acid in women with gestational hypertension. Hypertension. 2011; 58 (4): 704-8. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.177212
127. Bellos I., Pergialiotis V., Loutradis D., Daskalakis G. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020; 22 (5): 826-34. DOI: https://doi.org/10.1111/jch.13865
128. Ruotsalainen V., Ljungberg P., Wartiovaara J., Lenkkeri U., Kestilä M., Jalako H., et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA. 1999; 96 (14): 7962-7. DOI: https://doi.org/10.1073/pnas.96.14.7962
129. Wang Y, Zhao S, Loyd S, Groome L.J. Increased urinary excretion of nephrin, podocalyxin, and ßig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012; 302 (9): F1084-9. DOI: https://doi.org/10.1152/ajprenal.00597.2011
130. Yang G.Y., Lee K.A., Park M.H., Park H.S., Ha E.H., Chun S.H., et al. Urinary nephrin: A new predictive marker for pregnancies with preeclampsia and small-for-gestational age infants. Obstet Gynecol Sci. 2013; 56 (1): 22-8. DOI: https://doi.org/10.5468/OGS.2013.56.1.22
131. Son G.H., Kwon J.Y., Lee S., Park J., Kim Y.-J., Yun B., et al. Comparison of serum and urinary nephrin levels between normal pregnancies and severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2013; 166 (2): 139-44. DOI: https://doi.org/10.1016/j.ejogrb.2012.10.011
132. Jim B., Mehta S., Qipo A., Kim K., Cohen H.W., Moore R.M., et al. A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: A prospective study. PLoS One. 2014; 9: e101445. DOI: https://doi.org/10.1371/jornal.pone.0101445
133. Zhai T., Furuta I., Akaishi R., Kawabata K., Chiba K., Umazume T., et al. Feasibility of nephrinuria as a screening tool for the risk of preeclampsia: Prospective observational study. BMJ Open. 2016; 6 (8): e011229. DOI: https://doi.org/10.1136/bmjopen-2016-011229
134. Prajapati K., Nakum K. Prospective study to analyze calcium creatinine ratio in a spot sample of urine for early prediction of hypertensive disorders in pregnancy. Int J Med Biomed Stud. 2020; 4 (3): 52-6. DOI: https://doi.org/10.32553/ijmbs.v4i3.1027
135. Reis Z.S., Pereira J.B., Aparecida C.A., Barra J.S. Soluble endoglin in urine as an early-pregnancy preeclampsia marker: Antenatal longitudinal feasibility study. J Obstet Gynaecol. 2021; 41 (5): 693-8. DOI: https://doi.org/10.1080/01443615.2020.1789851
136. Scazzocchio E., Figueras F., Crispi F., Meler E., Masoller N., Mula R., Gratacos E. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013; 208 (3): 203.e1-10. DOI: https://doi.org/10.1016/j.ajog.2012.12.016
137. Onwudiwe N., Yu C.K.H., Poon L.C.Y., Spiliopoulos I., Nicolaides K.H. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol. 2008; 32 (7): 877-83. DOI: https://doi.org/10.1002/uog.6124
138. Phupong V., Dejthevaporn T. Predicting risks of preeclampsia and small for gestational age infant by uterine artery Doppler. Hypertens Pregnancy. 2008; 27 (4): 387-95. DOI: https://doi.org/10.1080/10641950801958059
139. Brandão A.H.F., Evangelista A.A., Martins R.M.F., Leite H.V., Cabral A.C.V. Prediction of early and late preeclampsia by flow-mediated dilation of the brachial artery. Radiol Bras. 2014; 47 (4): 206-9. DOI: https://doi.org/10.1590/0100-3984.2013.1894
140. Plasencia W., González-Dávila E., González Lorenzo A., Armas-González M., Padrón E., González-González N.L. First trimester placental volume and vascular indices in pregnancies complicated by preeclampsia. Prenatal Diagn. 2015; 35 (12): 1247-54. DOI: https://doi.org/10.1002/pd.4692
141. Hui L. Non-invasive prenatal testing for fetal aneuploidy: Charting the course from clinical validity to clinical utility. Ultrasound Obstet Gynecol. 2013; 41 (1): 2-6. DOI: https://doi.org/10.1002/uog.12360
142. Sifakis S.; Koukou Z.; Spandidos D.A. Cell-free fetal DNA and pregnancy-related complications (review). Mol Med Rep. 2015; 11 (4): 2367-72. DOI: https://doi.org/10.3892/mmr.2014.3118
143. Giguere Y., Charland M., Bujold E., Bernard N., Grenier S., Rousseau F., et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010; 56 (3): 361-75. DOI: https://doi.org/10.1373/clinchem.2009.134080
144. Bobrov M.Yu. Extracellular vesicles and miRNAs: Promising research objects for understanding the pathogenesis of preeclampsia. Medica mente. Lechim s umom [Medica mente. Treat Wisely]. 2016; (2)): 3-8. (in Russian) [Бобров М.Ю. Внеклеточные везикулы и микроРНК: перспективные объекты исследования для понимания патогенеза преэклампсии // Medica mente. Лечим с умом. 2016. № 2. С. 3-8.]
145. Salomon C., Yee S., Scholz-Romero K., et al. Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration. Front Pharmacol. 2014; 5: 175. DOI: https://doi.org/10.3389/fphar.2014.00175
146. Ouyang Y., Bayer A., Chu T., et al. Isolation of human trophoblastic extracellular vesicles and characterization of their cargo and antiviral activity. Placenta. 2016; 47: 86-95. DOI: https://doi.org10.1016/j.placenta.2016.09.008
147. Nielsen C.T., Ostergaard O., Johnsen C., Jacobsen S., Heegaard N.H.H. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum. 2011; 63 (10): 3067-77. DOI: https://doi.org/10.1002/art.20499
148. Stepanian A., Bourguignat L., Hennou S., Coupaye M., Hajage D., Salomon L., et al. Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity. 2013; 21 (11): 2236-43. DOI: https://doi.org/10.1002/oby.20365
149. Tramontano A.F., Lyubarova R., Tsiakos J., Palaia T.,Deleon J.R., Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm. 2010; 2010: 250476. DOI: https://doi.org/10.1155/2010/250476
150. Kambe S., Yoshitake H., Yuge K., Ishida Y., Moksed Ali M., Takizawa T., et al. Human exosomal placentaassociated miR-517a-3p modulates the expression of PRKG1 mRNA in Jurkat cells. Biol Reprod. 2014; 91 (5): 129. DOI: https://doi.org/10.1095/biolreprod.114.121616
151. Komaki M., Numata Y., Morioka C., Honda I., Tooi M., Yokoyama N., et al. Exosomes of human placenta-derived mesenchymal stem cells stimulate angiogenesis. Stem Cell Res Ther. 2017; 8 (1): 219. DOI: https://doi.org/10.1186/s13287-017-0660-9
152. Mouillet J.F., Ouyang Y., Bayer A., Coyne C.B., Sadovsky Y. The role of trophoblastic microRNAs in placental viral infection. Int J Dev Biol. 2014; 58 (2-4): 281-9. DOI: https://doi.org/10.1387/ijdb.130349ys
153. Biró O., Fóthi Á., Alasztics B., Nagy B., Orbán T.I., Rigó J. Jr. Circulating exosomal and Argonaute-bound microRNAs in preeclampsia. Gene. 2019; 692: 138-44. DOI: https://doi.org/10.1016/j.gene.2019.01.012
154. Shen L., Li Y., Li R., Diao Z., Yany M., Wu M., et al. Placenta-associated serum exosomal miR-155 derived from patients with preeclampsia inhibits eNOS expression in human umbilical vein endothelial cells. Int J Mol Med. 2018; 41 (3): 1731-9. DOI: https://doi.org/10.3892/ijmm.2018.3367